Biopharmaceutical companies tackle clinical trial transparency

  • Dan McDonald
  • Steve Zisson


Pharmaceutical Company Clinical Trial Registry Clinical Trial Result Clinical Trial Protocol Active Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pharmaceutical Research and Manufacturing Association. Pharmaceutical companies to make more information available about clinical trials. Available at cfm (Accessed 13 March 2005)Google Scholar
  2. 2.
    United States Food and Drug Administration. Section 113 Food and Drug Administration Modernization Act of 1997. Available at: (Accessed 8 February 2006)Google Scholar
  3. 3.
    Office of the New York State Attorney General Eliot Spitzer. Major pharmaceutical firm concealed information. Available at (Accessed 17 March 2005)Google Scholar
  4. 4.
    Fair Access to Clinical Trials Act of 2005. US Senate S470. Available at (Accessed 21 March 2005)Google Scholar
  5. 5.
    Pharmaceutical Research and Manufacturing Association. International alliance of pharmaceutical associations agrees on principles for disclosing information. Available at (Accessed 13 March 2005)Google Scholar
  6. 6.
    CenterWatch (2005) Clinical trial transparency efforts multiple. The CenterWatch Monthly 12(11): 1–13Google Scholar
  7. 7.
    World Health Organization. WHO International Clinical Trials Registration Platform: Unique ID assignment. Geneva: WHO. Available at (Accessed 23 January 2006)Google Scholar
  8. 8.
    Haug C, Gøtzsche PC, Schroeder TV (2005) Registries and registration of clinical trials. N Engl J Med 353: 2811–2812PubMedCrossRefGoogle Scholar
  9. 9.
    McDonald D, Molnari PM (2005) Breaking the trial result disclosure logjam now. Appl Clin Trials 11: 37–38Google Scholar
  10. 10.
    F Hoffman-La Roche. Roche clinical trial registry and results database launched on Available at (Accessed 16 February 2006)Google Scholar
  11. 11.
    Metz C. Interpretation and next steps to achieve an acceptable blend of the position statement. Clinical Trial Registries and Registers Conference, Pharmaceutical Education Associates, Philadelphia, PA; September 22–23, 2005.Google Scholar
  12. 12.
    Maine Department of Health and Human Services. Clinical Trial Registration Law Summary. Available at (Accessed 16 February 2006)Google Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2006

Authors and Affiliations

  • Dan McDonald
    • 1
  • Steve Zisson
    • 1
  1. 1.Thomson CenterWatchBostonUSA

Personalised recommendations